An allosteric inhibitor of sirtuin 2 deacetylase activity exhibits broad-spectrum antiviral activity
Journal of Clinical Investigation · 15.06.2023 · 133 (12)
DOI: 10.1172/jci158978 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 15.06.2023. Verfasst von Kathryn L Roche und 15 weiteren Autor:innen. Beteiligte Einrichtung: Evrys Bio LLC, Pennsylvania Biotechnology Center, Doylestown, Pennsylvania, USA. Hauptthemen laut MEDLINE: Coronavirus, Coronavirus Infections. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NCI NIH HHS, NIH.
Abstract (Originalsprache)
Most drugs used to treat viral disease target a virus-coded product. They inhibit a single virus or virus family, and the pathogen can readily evolve resistance. Host-targeted antivirals can overcome these limitations. The broad-spectrum activity achieved by host targeting can be especially useful in combating emerging viruses and for treatment of diseases caused by multiple viral pathogens, such as opportunistic agents in immunosuppressed patients. We have developed a family of compounds that modulate sirtuin 2, an NAD+-dependent deacylase, and now report the properties of a member of that family, FLS-359. Biochemical and x-ray structural studies show that the drug binds to sirtuin 2 and allosterically inhibits its deacetylase activity. FLS-359 inhibits the growth of RNA and DNA viruses, including members of the coronavirus, orthomyxovirus, flavivirus, hepadnavirus, and herpesvirus families. FLS-359 acts at multiple levels to antagonize cytomegalovirus replication in fibroblasts, causing modest reductions in viral RNAs and DNA, together with a much greater reduction in infectious progeny, and it exhibits antiviral activity in humanized mouse models of infection. Our results highlight the potential of sirtuin 2 inhibitors as broad-spectrum antivirals and set the stage for further understanding of how host epigenetic mechanisms impact the growth and spread of viral pathogens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Evrys Bio LLC, Pennsylvania Biotechnology Center, Doylestown, Pennsylvania, USA.
- Department of Molecular Genetics and Microbiology, Duke Center for Virology, Duke University School of Medicine, Durham, North Carolina, USA.
- International Center for the Advancement of Translational Science, Division of Infectious Diseases, Center for AIDS Research, University of North Carolina, School of Medicine, Chapel Hill, North Carolina, USA.
- TICRO Bioservices, Trudeau Institute, Saranac Lake, New York, USA.
- Department of Molecular Biology, Princeton University, Princeton, New Jersey, USA.
- Microbiology and Immunology Department, SUNY Upstate Medical University, Syracuse, New York, USA.
Förderung
- NIAID NIH HHS
- NCI NIH HHS
- NIH
- U.S. Department of Defense
Zitieren
APA
Roche, K. L., Remiszewski, S., Todd, M. J., Kulp, J. L., Tang, L., Welsh, A. V., Barry, A. P., De, C., Reiley, W. W., Wahl, A., Garcia, J. V., Luftig, M. A., Shenk, T., Tonra, J. R., Murphy, E. A., & Chiang, L. W. (2023). An allosteric inhibitor of sirtuin 2 deacetylase activity exhibits broad-spectrum antiviral activity. Journal of Clinical Investigation, 133(12). https://doi.org/10.1172/jci158978
Vancouver
Roche KL, Remiszewski S, Todd MJ, Kulp JL, Tang L, Welsh AV, et al. An allosteric inhibitor of sirtuin 2 deacetylase activity exhibits broad-spectrum antiviral activity. Journal of Clinical Investigation. 2023;133(12). doi:10.1172/jci158978
BibTeX
@article{Roche2023,
author = {Roche, Kathryn L and Remiszewski, Stacy and Todd, Matthew J and Kulp, John L and Tang, Liudi and Welsh, Alison V and Barry, Ashley P and De, Chandrav and Reiley, William W and Wahl, Angela and Garcia, J Victor and Luftig, Micah A and Shenk, Thomas and Tonra, James R and Murphy, Eain A and Chiang, Lillian W},
title = {An allosteric inhibitor of sirtuin 2 deacetylase activity exhibits broad-spectrum antiviral activity},
journal = {Journal of Clinical Investigation},
year = {2023},
volume = {133},
number = {12},
doi = {10.1172/jci158978}
}
EUVIMED